Margo Heath‐Chiozzi

2.4k total citations
22 papers, 1.7k citations indexed

About

Margo Heath‐Chiozzi is a scholar working on Virology, Infectious Diseases and Rheumatology. According to data from OpenAlex, Margo Heath‐Chiozzi has authored 22 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Virology, 7 papers in Infectious Diseases and 5 papers in Rheumatology. Recurrent topics in Margo Heath‐Chiozzi's work include HIV Research and Treatment (9 papers), HIV/AIDS Research and Interventions (7 papers) and HIV/AIDS drug development and treatment (7 papers). Margo Heath‐Chiozzi is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS Research and Interventions (7 papers) and HIV/AIDS drug development and treatment (7 papers). Margo Heath‐Chiozzi collaborates with scholars based in United States, Germany and United Kingdom. Margo Heath‐Chiozzi's co-authors include Brian B. Spear, John M. Leonard, Eugene Sun, Richard A. Rode, Sven A. Danner, D. William Cameron, David Henry, Stephen Kravcik, Clement Maurath and Calvin Cohen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Margo Heath‐Chiozzi

22 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margo Heath‐Chiozzi United States 13 852 801 265 206 175 22 1.7k
Margalida Rotger Switzerland 23 1.1k 1.3× 849 1.1× 266 1.0× 168 0.8× 245 1.4× 40 1.9k
Janez Tomažič Slovenia 15 542 0.6× 334 0.4× 323 1.2× 229 1.1× 111 0.6× 51 1.7k
N J Fitch United Kingdom 9 691 0.8× 874 1.1× 320 1.2× 422 2.0× 269 1.5× 14 2.1k
K. Tsuchiya Japan 23 805 0.9× 523 0.7× 229 0.9× 133 0.6× 254 1.5× 76 1.6k
Takuma Shirasaka Japan 21 696 0.8× 539 0.7× 337 1.3× 195 0.9× 210 1.2× 87 1.4k
Cassy Workman Australia 16 1.2k 1.4× 1.3k 1.6× 359 1.4× 514 2.5× 217 1.2× 30 2.7k
Sorin Rugină Romania 11 441 0.5× 259 0.3× 249 0.9× 210 1.0× 108 0.6× 65 1.6k
Mauro Sciandra Italy 26 1.0k 1.2× 707 0.9× 488 1.8× 171 0.8× 214 1.2× 53 1.7k
Gabriela Bleiber Switzerland 19 841 1.0× 830 1.0× 244 0.9× 193 0.9× 225 1.3× 24 1.5k
William Spreen United States 30 2.4k 2.8× 1.8k 2.3× 693 2.6× 381 1.8× 287 1.6× 80 3.6k

Countries citing papers authored by Margo Heath‐Chiozzi

Since Specialization
Citations

This map shows the geographic impact of Margo Heath‐Chiozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margo Heath‐Chiozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margo Heath‐Chiozzi more than expected).

Fields of papers citing papers by Margo Heath‐Chiozzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margo Heath‐Chiozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margo Heath‐Chiozzi. The network helps show where Margo Heath‐Chiozzi may publish in the future.

Co-authorship network of co-authors of Margo Heath‐Chiozzi

This figure shows the co-authorship network connecting the top 25 collaborators of Margo Heath‐Chiozzi. A scholar is included among the top collaborators of Margo Heath‐Chiozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margo Heath‐Chiozzi. Margo Heath‐Chiozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maurer, Marcus, Martin Metz, John Anderson, et al.. (2025). Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria. Allergy. 80(8). 2178–2186. 6 indexed citations
2.
Maurer, Marcus, Martin Metz, John Anderson, et al.. (2023). Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria. Journal of Allergy and Clinical Immunology. 151(2). AB133–AB133. 5 indexed citations
3.
Terhorst‐Molawi, Dorothea, Tomasz Hawro, Lea Kiefer, et al.. (2022). Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 78(5). 1269–1279. 81 indexed citations
4.
Alvarado, Diego, Marcus Maurer, Richard Gedrich, et al.. (2022). Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 77(8). 2393–2403. 62 indexed citations
5.
Terhorst‐Molawi, Dorothea, Tomasz Hawro, Lea Kiefer, et al.. (2022). The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria (Cindu). Journal of Allergy and Clinical Immunology. 149(2). AB178–AB178. 6 indexed citations
6.
Bauman, Julie E., Ricklie Julian, Nabil F. Saba, et al.. (2022). Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. Cancers. 14(10). 2355–2355. 8 indexed citations
7.
Bauman, Julie E., Nabil F. Saba, Trisha M. Wise‐Draper, et al.. (2019). CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 37(15_suppl). 6025–6025. 7 indexed citations
8.
Spear, Brian B., et al.. (2001). Clinical application of pharmacogenetics. Trends in Molecular Medicine. 7(5). 201–204. 403 indexed citations
9.
Spear, B B, Margo Heath‐Chiozzi, Diane Barnes, et al.. (2001). Terminology for sample collection in clinical genetic studies. The Pharmacogenomics Journal. 1(2). 101–103. 13 indexed citations
10.
Raines, Charles, Charles Flexner, Eugene Sun, et al.. (2000). Safety, Tolerability, and Antiretroviral Effects of Ritonavir-Nelfinavir Combination Therapy Administered for 48 Weeks. JAIDS Journal of Acquired Immune Deficiency Syndromes. 322–328. 6 indexed citations
11.
Valdez, Hernán, Kimberly Y. Smith, Alan Landay, et al.. (2000). Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. AIDS. 14(1). 11–21. 127 indexed citations
12.
13.
Markowitz, Martin, Mika Vesanen, Klara Tenner‐Racz, et al.. (1999). The Effect of Commencing Combination Antiretroviral Therapy Soon after Human Immunodeficiency Virus Type 1 Infection on Viral Replication and Antiviral Immune Responses. The Journal of Infectious Diseases. 179(3). 527–537. 151 indexed citations
14.
Cameron, D. William, Margo Heath‐Chiozzi, Sven A. Danner, et al.. (1998). Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Lancet. 351(9102). 543–549. 427 indexed citations
15.
Mueller, Brigitta U., Steven L. Zeichner, Vladimir A. Kuznetsov, et al.. (1998). Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS. 12(15). F191–F196. 31 indexed citations
16.
Kempf, Dale J., Richard A. Rode, Yi Xu, et al.. (1998). The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 12(5). F9–F14. 172 indexed citations
17.
Flanigan, Timothy, Bharat Ramratnam, James Hellinger, et al.. (1996). Prospective trial of paromomycin for cryptosporidiosis in AIDS. The American Journal of Medicine. 100(3). 370–372. 24 indexed citations
18.
19.
Jacobson, Mark Z., Michael Wulfsohn, Judith Feinberg, et al.. (1994). Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093). AIDS. 8(4). 451–460. 17 indexed citations
20.
Crumpacker, Clyde S. & Margo Heath‐Chiozzi. (1991). Overview of cytomegalovirus infections in HIV-infected patients: current therapies and future strategies.. PubMed. 4 Suppl 1. S1–5. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margalida Rotger Breakdown of academic impact, for papers by Janez Tomažič Breakdown of academic impact, for papers by N J Fitch Breakdown of academic impact, for papers by K. Tsuchiya Breakdown of academic impact, for papers by Takuma Shirasaka Breakdown of academic impact, for papers by Cassy Workman Breakdown of academic impact, for papers by Sorin Rugină Breakdown of academic impact, for papers by Mauro Sciandra Breakdown of academic impact, for papers by Gabriela Bleiber Breakdown of academic impact, for papers by William Spreen
Rankless by CCL
2026